Unknown

Dataset Information

0

Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy.


ABSTRACT: Anti-MAG (myelin-associated glycoprotein) neuropathy is a disabling autoimmune peripheral neuropathy caused by monoclonal IgM autoantibodies that recognize the carbohydrate epitope HNK-1 (human natural killer-1). This glycoepitope is highly expressed on adhesion molecules, such as MAG, present in myelinated nerve fibers. Because the pathogenicity and demyelinating properties of anti-MAG autoantibodies are well established, current treatments are aimed at reducing autoantibody levels. However, current therapies are primarily immunosuppressive and lack selectivity and efficacy. We therefore hypothesized that a significant improvement in the disease condition could be achieved by selectively neutralizing the pathogenic anti-MAG antibodies with carbohydrate-based ligands mimicking the natural HNK-1 glycoepitope 1. In an inhibition assay, a mimetic (2, mimHNK-1) of the natural HNK-1 epitope blocked the interaction of MAG with pathogenic IgM antibodies from patient sera but with only micromolar affinity. Therefore, considering the multivalent nature of the MAG-IgM interaction, polylysine polymers of different sizes were substituted with mimetic 2. With the most promising polylysine glycopolymer PL84(mimHNK-1)45 the inhibitory effect on patient sera could be improved by a factor of up to 230,000 per epitope, consequently leading to a low-nanomolar inhibitory potency. Because clinical studies indicate a correlation between the reduction of anti-MAG IgM levels and clinical improvement, an immunological surrogate mouse model for anti-MAG neuropathy producing high levels of anti-MAG IgM was developed. The observed efficient removal of these antibodies with the glycopolymer PL84(mimHNK-1)45 represents an important step toward an antigen-specific therapy for anti-MAG neuropathy.

SUBMITTER: Herrendorff R 

PROVIDER: S-EPMC5422814 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy.

Herrendorff Ruben R   Hänggi Pascal P   Pfister Hélène H   Yang Fan F   Demeestere Delphine D   Hunziker Fabienne F   Frey Samuel S   Schaeren-Wiemers Nicole N   Steck Andreas J AJ   Ernst Beat B  

Proceedings of the National Academy of Sciences of the United States of America 20170417 18


Anti-MAG (myelin-associated glycoprotein) neuropathy is a disabling autoimmune peripheral neuropathy caused by monoclonal IgM autoantibodies that recognize the carbohydrate epitope HNK-1 (human natural killer-1). This glycoepitope is highly expressed on adhesion molecules, such as MAG, present in myelinated nerve fibers. Because the pathogenicity and demyelinating properties of anti-MAG autoantibodies are well established, current treatments are aimed at reducing autoantibody levels. However, cu  ...[more]

Similar Datasets

| S-EPMC7497077 | biostudies-literature
| S-EPMC6468000 | biostudies-literature
| S-EPMC6244677 | biostudies-literature
| S-EPMC9300200 | biostudies-literature
| S-EPMC39902 | biostudies-other
| S-EPMC5992033 | biostudies-literature
| S-EPMC3334283 | biostudies-literature
| S-EPMC2877104 | biostudies-literature
| S-EPMC6148974 | biostudies-literature